Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-02-23

FDA Approved: PEMAZYRE — Supplemental Application (Incyte Corporation)

View source ↗

Summary

The FDA approved a supplemental application for Pemazyre (pemigatinib) from Incyte Corporation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pemazyre (pemigatinib)

Snippet

SUPPL AP for PEMAZYRE (PEMIGATINIB)